Pulsenmore Expands U.S. Presence with New Home Ultrasound Partnership
PLSM is trading near its 52-week low of $5.569 (5.9% above the low) on light trading volume (0.4× avg).
Summary
Pulsenmore Ltd. announced a new commercial engagement with TLC Perinatal PA, a maternal-fetal medicine practice in Maryland, to integrate its home ultrasound services into their care model, marking continued U.S. expansion.
Key Events · M&A and Partnerships · PLSM
-
Secures New U.S. Commercial Engagement
Pulsenmore entered a services agreement with TLC Perinatal PA in Maryland to integrate its Early Screening (ES) home ultrasound services.
-
Expands U.S. Market Rollout
This marks another step in the company's growing U.S. commercial operations, following its initial engagement earlier this month on 2026-02-02 and recent Nasdaq registration on 2026-01-27.
-
Validates Hybrid Care Model
The partnership will allow patients to perform ultrasound scans at home as part of a physician-directed hybrid care pathway, enhancing access and convenience.
Analysis · PLSM · Industrial Applications And Services
This filing highlights Pulsenmore's continued momentum in the U.S. market following its recent FDA clearance and initial commercial engagement. The partnership with TLC Perinatal PA, a specialized maternal-fetal medicine practice, demonstrates increasing adoption of Pulsenmore's home ultrasound technology. This expansion is crucial for the company's growth strategy, validating its patient-centric approach and extending prenatal care access through a hybrid care pathway. Investors should view this as a positive step in the company's U.S. rollout, indicating successful execution and market penetration.
At the time of this filing, PLSM was trading at $5.90 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $37.4M. The 52-week trading range was $5.57 to $10.28. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.